Forsta AP Fonden Sells 200 Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Forsta AP Fonden lessened its position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 0.2% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 97,200 shares of the medical equipment provider’s stock after selling 200 shares during the period. Forsta AP Fonden’s holdings in Zimmer Biomet were worth $10,267,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in ZBH. Dunhill Financial LLC increased its holdings in shares of Zimmer Biomet by 1,090.0% during the third quarter. Dunhill Financial LLC now owns 238 shares of the medical equipment provider’s stock worth $26,000 after purchasing an additional 218 shares during the period. Ashton Thomas Securities LLC bought a new position in shares of Zimmer Biomet in the third quarter worth $28,000. Bangor Savings Bank acquired a new position in Zimmer Biomet in the third quarter valued at about $31,000. Brooklyn Investment Group bought a new stake in Zimmer Biomet during the third quarter worth about $35,000. Finally, Quarry LP acquired a new position in shares of Zimmer Biomet in the 2nd quarter valued at approximately $53,000. Institutional investors and hedge funds own 88.89% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on the stock. Needham & Company LLC reissued a “hold” rating on shares of Zimmer Biomet in a report on Wednesday. Truist Financial raised their price objective on shares of Zimmer Biomet from $117.00 to $118.00 and gave the stock a “hold” rating in a research report on Wednesday, December 18th. BTIG Research cut their target price on shares of Zimmer Biomet from $134.00 to $126.00 and set a “buy” rating on the stock in a research note on Thursday, October 3rd. JPMorgan Chase & Co. upgraded shares of Zimmer Biomet from a “neutral” rating to an “overweight” rating and raised their price target for the stock from $125.00 to $128.00 in a report on Tuesday, December 17th. Finally, Barclays dropped their price objective on shares of Zimmer Biomet from $125.00 to $118.00 and set an “underweight” rating on the stock in a report on Thursday, December 12th. Two research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and nine have issued a buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $124.11.

Zimmer Biomet Stock Performance

NYSE ZBH opened at $110.63 on Friday. The company has a fifty day moving average price of $107.91 and a 200-day moving average price of $108.22. The firm has a market cap of $22.02 billion, a price-to-earnings ratio of 21.03, a PEG ratio of 1.88 and a beta of 1.02. The company has a debt-to-equity ratio of 0.38, a current ratio of 1.36 and a quick ratio of 0.70. Zimmer Biomet Holdings, Inc. has a 1 year low of $100.67 and a 1 year high of $133.90.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings data on Wednesday, October 30th. The medical equipment provider reported $1.74 EPS for the quarter, meeting the consensus estimate of $1.74. Zimmer Biomet had a net margin of 14.27% and a return on equity of 12.95%. The firm had revenue of $1.82 billion during the quarter, compared to analyst estimates of $1.80 billion. During the same quarter last year, the business posted $1.65 EPS. The company’s revenue for the quarter was up 4.1% on a year-over-year basis. As a group, equities research analysts predict that Zimmer Biomet Holdings, Inc. will post 7.99 EPS for the current fiscal year.

Zimmer Biomet Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, January 31st. Shareholders of record on Monday, December 30th will be given a $0.24 dividend. The ex-dividend date is Monday, December 30th. This represents a $0.96 annualized dividend and a yield of 0.87%. Zimmer Biomet’s dividend payout ratio is currently 18.25%.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.